The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months

Jay M Sosenko, Jay S Skyler, Craig A. Beam, David Boulware, Jeffrey L. Mahon, Jeffrey P. Krischer, Carla J. Greenbaum, Lisa Rafkin, Della Matheson, Kevan C. Herold, Jerry P. Palmer

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

OBJECTIVE: We developed a scale to serve as a potential end point for 6-month glycemic progression (PS6M) toward type 1 diabetes (T1D) in autoantibody-positive relatives of individuals with T1D. RESEARCH DESIGN AND METHODS: The PS6M was developed from Diabetes Prevention Trial-Type 1 (DPT-1) data and tested in the TrialNet Pathway to Prevention Study (PTP). It is the difference between 6-month glucose sum values (30-120 min oral glucose tolerance test values) and values predicted for nonprogressors. RESULTS: The PS6M predicted T1D in the PTP (P <0.001). The area under the receiver operating chacteristic curve was greater (P <0.001) for the PS6M than for the baseline-to-6-month difference. PS6M values were higher in those with two or more autoantibodies, 30-0 min C-peptide values 7.00 (P <0.001 for all). CONCLUSIONS: The PS6M is an indicator of short-term glycemic progression to T1D that could be a useful tool for assessing preventive treatments and biomarkers.

Original languageEnglish (US)
Pages (from-to)940-942
Number of pages3
JournalDiabetes Care
Volume38
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

Type 1 Diabetes Mellitus
Autoantibodies
C-Peptide
Glucose Tolerance Test
Research Design
Biomarkers
Glucose

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months. / Sosenko, Jay M; Skyler, Jay S; Beam, Craig A.; Boulware, David; Mahon, Jeffrey L.; Krischer, Jeffrey P.; Greenbaum, Carla J.; Rafkin, Lisa; Matheson, Della; Herold, Kevan C.; Palmer, Jerry P.

In: Diabetes Care, Vol. 38, No. 5, 01.05.2015, p. 940-942.

Research output: Contribution to journalArticle

Sosenko, JM, Skyler, JS, Beam, CA, Boulware, D, Mahon, JL, Krischer, JP, Greenbaum, CJ, Rafkin, L, Matheson, D, Herold, KC & Palmer, JP 2015, 'The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months', Diabetes Care, vol. 38, no. 5, pp. 940-942. https://doi.org/10.2337/dc14-2787
Sosenko, Jay M ; Skyler, Jay S ; Beam, Craig A. ; Boulware, David ; Mahon, Jeffrey L. ; Krischer, Jeffrey P. ; Greenbaum, Carla J. ; Rafkin, Lisa ; Matheson, Della ; Herold, Kevan C. ; Palmer, Jerry P. / The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months. In: Diabetes Care. 2015 ; Vol. 38, No. 5. pp. 940-942.
@article{709ac6de3dbc4d85a76b69a009029a40,
title = "The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months",
abstract = "OBJECTIVE: We developed a scale to serve as a potential end point for 6-month glycemic progression (PS6M) toward type 1 diabetes (T1D) in autoantibody-positive relatives of individuals with T1D. RESEARCH DESIGN AND METHODS: The PS6M was developed from Diabetes Prevention Trial-Type 1 (DPT-1) data and tested in the TrialNet Pathway to Prevention Study (PTP). It is the difference between 6-month glucose sum values (30-120 min oral glucose tolerance test values) and values predicted for nonprogressors. RESULTS: The PS6M predicted T1D in the PTP (P <0.001). The area under the receiver operating chacteristic curve was greater (P <0.001) for the PS6M than for the baseline-to-6-month difference. PS6M values were higher in those with two or more autoantibodies, 30-0 min C-peptide values 7.00 (P <0.001 for all). CONCLUSIONS: The PS6M is an indicator of short-term glycemic progression to T1D that could be a useful tool for assessing preventive treatments and biomarkers.",
author = "Sosenko, {Jay M} and Skyler, {Jay S} and Beam, {Craig A.} and David Boulware and Mahon, {Jeffrey L.} and Krischer, {Jeffrey P.} and Greenbaum, {Carla J.} and Lisa Rafkin and Della Matheson and Herold, {Kevan C.} and Palmer, {Jerry P.}",
year = "2015",
month = "5",
day = "1",
doi = "10.2337/dc14-2787",
language = "English (US)",
volume = "38",
pages = "940--942",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "5",

}

TY - JOUR

T1 - The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months

AU - Sosenko, Jay M

AU - Skyler, Jay S

AU - Beam, Craig A.

AU - Boulware, David

AU - Mahon, Jeffrey L.

AU - Krischer, Jeffrey P.

AU - Greenbaum, Carla J.

AU - Rafkin, Lisa

AU - Matheson, Della

AU - Herold, Kevan C.

AU - Palmer, Jerry P.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - OBJECTIVE: We developed a scale to serve as a potential end point for 6-month glycemic progression (PS6M) toward type 1 diabetes (T1D) in autoantibody-positive relatives of individuals with T1D. RESEARCH DESIGN AND METHODS: The PS6M was developed from Diabetes Prevention Trial-Type 1 (DPT-1) data and tested in the TrialNet Pathway to Prevention Study (PTP). It is the difference between 6-month glucose sum values (30-120 min oral glucose tolerance test values) and values predicted for nonprogressors. RESULTS: The PS6M predicted T1D in the PTP (P <0.001). The area under the receiver operating chacteristic curve was greater (P <0.001) for the PS6M than for the baseline-to-6-month difference. PS6M values were higher in those with two or more autoantibodies, 30-0 min C-peptide values 7.00 (P <0.001 for all). CONCLUSIONS: The PS6M is an indicator of short-term glycemic progression to T1D that could be a useful tool for assessing preventive treatments and biomarkers.

AB - OBJECTIVE: We developed a scale to serve as a potential end point for 6-month glycemic progression (PS6M) toward type 1 diabetes (T1D) in autoantibody-positive relatives of individuals with T1D. RESEARCH DESIGN AND METHODS: The PS6M was developed from Diabetes Prevention Trial-Type 1 (DPT-1) data and tested in the TrialNet Pathway to Prevention Study (PTP). It is the difference between 6-month glucose sum values (30-120 min oral glucose tolerance test values) and values predicted for nonprogressors. RESULTS: The PS6M predicted T1D in the PTP (P <0.001). The area under the receiver operating chacteristic curve was greater (P <0.001) for the PS6M than for the baseline-to-6-month difference. PS6M values were higher in those with two or more autoantibodies, 30-0 min C-peptide values 7.00 (P <0.001 for all). CONCLUSIONS: The PS6M is an indicator of short-term glycemic progression to T1D that could be a useful tool for assessing preventive treatments and biomarkers.

UR - http://www.scopus.com/inward/record.url?scp=84958651977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958651977&partnerID=8YFLogxK

U2 - 10.2337/dc14-2787

DO - 10.2337/dc14-2787

M3 - Article

C2 - 25758770

AN - SCOPUS:84958651977

VL - 38

SP - 940

EP - 942

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 5

ER -